Provided by Tiger Trade Technology Pte. Ltd.

Aptevo Therapeutics

4.27
-0.2400-5.32%
Post-market: 4.270.0016+0.04%19:58 EDT
Volume:82.75K
Turnover:362.06K
Market Cap:5.05M
PE:-0.01
High:4.55
Open:4.50
Low:4.14
Close:4.51
52wk High:1,299.60
52wk Low:3.95
Shares:1.18M
Float Shares:1.18M
Volume Ratio:2.72
T/O Rate:7.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-351.3949
EPS(LYR):-1,747.6642
ROE:-242.74%
ROA:-79.19%
PB:0.29
PE(LYR):0.00

Loading ...

Roth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)

TIPRANKS
·
Mar 27

Aptevo Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Mar 27

Aptevo Therapeutics Q4 EPS $(6.23) Beats $(8.10) Estimate

Benzinga
·
Mar 26

Aptevo Therapeutics reports FY25 EPS ($87.27) vs. ($31,460.23) last year

TIPRANKS
·
Mar 26

Aptevo Therapeutics sees cash runway into 4Q26

TIPRANKS
·
Mar 26

Aptevo Therapeutics FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million

Reuters
·
Mar 26

Aptevo highlights mipletamig AML data showing 79% remission rate

Reuters
·
Mar 23

Aptevo Therapeutics to present at Roth Conference and BIO-Europe Spring

Reuters
·
Mar 19

Aptevo reports 86% clinical benefit rate and 0% CRS for mipletamig plus venetoclax and azacitidine in frontline AML trial data

Reuters
·
Mar 11

Roth MKM Keeps Their Buy Rating on Aptevo Therapeutics (APVO)

TIPRANKS
·
Mar 11

Aptevo Therapeutics Inc expected to post a loss of $8.10 a share - Earnings Preview

Reuters
·
Feb 20

Aptevo Therapeutics Shareholders Approve Expanded Equity Financing Capacity

TIPRANKS
·
Feb 19

Aptevo Therapeutics Inc. Held Special Stockholder Meeting

Reuters
·
Feb 19

Aptevo Therapeutics Announces CEO Transition and Leadership Changes

TIPRANKS
·
Feb 03

BRIEF-Aptevo Therapeutics Inc - Marvin White To Retire As Aptevo CEO Effective April 1, 2026 - SEC Filing

Reuters
·
Feb 03

Aptevo Therapeutics Inc - Marvin White to Retire as Aptevo CEO Effective April 1, 2026 - SEC Filing

THOMSON REUTERS
·
Feb 03

Aptevo Therapeutics ernennt Jeff Lamothe zum neuen CEO

Reuters
·
Feb 03

Aptevo Therapeutics Prospectus Relates To Offer And Sale Of Up To 7,075,471 Shares Of Our Common Stock By Selling Stockholder

Reuters
·
Jan 29

Aptevo Therapeutics Inc - Prospectus Relates to Offer and Sale of up to 7,075,471 Shares of Our Common Stock by Selling Stockholder - Filing

THOMSON REUTERS
·
Jan 29

Aptevo Therapeutics Secures $60 Million Equity Financing Facility

TIPRANKS
·
Jan 09